Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Merck (MRK) agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its bestselling cancer drug.
- The Pentagon has agreed with major defense contractors on a series of framework agreements meant to accelerate production of key missile systems that have seen heavy use during the initial phases of the US and Israeli war against Iran. Lockheed Martin and BAE Systems agreed with the Defense Department on plans to “quadruple the production of seekers for the Terminal High Altitude Area Defense (THAAD) interceptor,” according to a Pentagon announcement.
- Chewy (CHWY) shares rise after the online retailer of pet products gave a net sales forecast for the fiscal year 2027 that beat the average analyst estimate.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Merck & Co (MRK) to buy Terns Pharmaceuticals (TERN) for $53/share in cash for an approximate equity value of $6.7 billion.
- Shares of Arm Holdings (ARM), which made its name licensing technology to semiconductor makers, rose in premarket trading after it said it will sell its own chips for the first time, in a move forecast to generate about $15 billion annually within five years.
- Braze shares rise after the software company forecast revenue for the first quarter that was higher than the average analyst estimate.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- KB Home (KBH) shares are down 5% in postmarket trading Tuesday after the single-family home builder reported forecast deliveries for the second quarter that missed the average analyst estimate.

- Arm Holdings (ARM) which made its name licensing technology to semiconductor makers, will begin selling its own chips for the first time, adding a business that it expects to generate about $15 billion annually within five years. Shares closed down 1.41%.

- ImmunityBio (IBRX)shares plunged after the biotechnology company and its billionaire executive chairman, Patrick Soon-Shiong, were hit with a Food and Drug Administration warning letter for false and misleading promotion of its bladder cancer drug Anktiva.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- US coal stocks climb on Tuesday as the Iran war continues and the tightened supply of liquefied natural gas is expected to increase demand for coal. Among gainers: Peabody Energy +9.3%, Core Natural Resources +7.0%, Hallador Energy +5.0%, Alliance Resource Partners +2.9%, Alpha Metallurgical Resources +8.7%, Warrior Met Coal +9.4%

-Circle Internet Group (CRCL) the issuer of the USDC stablecoin, fell the most on record on Tuesday, with investors reacting to potential changes to stablecoin regulation that could make the firm’s cryptocurrency less attractive to large holders. Concerns that a competitor is readying a move into the US market also hurt Circle’s share price. The stock declined as much as 22%, its steepest intraday drop ever, and leading losses across crypto-linked equities.

- Uber (UBER) shares slide 2.1% on Tuesday as the rideshare giant is in talks to acquire German premium chauffeur services provider Blacklane, Manager Magazin reports citing unidentified people familiar.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Concentrix (CNXC) shares fall as the software company’s second-quarter forecast was weaker than expected. Vital Knowledge also notes “a modest shortfall on FQ1 EPS,” given margin compression.
- Jefferies (JEF) shares are mixed. Hedge fund founder George Weiss has lost his defamation suit accusing Jefferies Financial Group of running a “smear campaign” to pressure him to pay a $100 million debt owed by his firm, Weiss Multi-Strategy Advisers.
- ImmunityBio (IBRX) shares fell as much as 25%, the most intraday since 2024, after the FDA warned Anktiva ads are false and misleading, citing unapproved claims and regulatory violations.
See omnystudio.com/listener for privacy information.